Hydroxychloroquine has one approved way of reaching a patient: as an oral tablet, almost always in a 200mg strength. That simple fact surprises many people who search for it expecting to find a menu of creams, injections, or liquid options. This article explains what that 200mg tablet actually contains, why the number on the label is not quite as straightforward as it looks, how generic versions differ from the original brand, and where the real evidence stands on its uses — including the uses it was never approved for.
What Hydroxychloroquine Is, and Where It Came From
Hydroxychloroquine is a synthetic descendant of quinine, the compound isolated from the bark of the South American cinchona tree that has been used against malaria for centuries. Chemists modified quinine's molecular cousin, chloroquine, in the 1940s to reduce its toxicity while keeping its usefulness against malaria parasites and, later, against certain autoimmune diseases. It is a fair thing to notice, in an age of laboratory-built medicine, that this line of treatment ultimately traces back to a tree bark that people learned to use long before anyone understood why it worked. That is not a scientific argument for anything, but it is a reminder that the created world has offered up real remedies, and that careful human study of those remedies has genuine value.
In the United States, hydroxychloroquine is approved by the FDA for three indications: treatment and suppression of malaria in sensitive strains, treatment of chronic discoid and systemic lupus erythematosus, and treatment of rheumatoid arthritis. It is not approved for COVID-19 or any other viral illness, a point worth stating plainly before going further.
The Only Marketed Form: The 200mg Oral Tablet
Every legally marketed hydroxychloroquine product sold in pharmacies is hydroxychloroquine sulfate, formulated as a film-coated oral tablet, and in the United States it comes in one strength: 200mg. There is no FDA-approved liquid, injectable, or topical hydroxychloroquine product on the market. When people ask what "hydroxychloroquine 200mg" or "HCQ tablets" look like, they are really asking about this single tablet.
Physically, the tablets are typically small, round or oval, biconvex, and film-coated in white or off-white. The coating is not cosmetic decoration; it masks the drug's intensely bitter taste and reduces stomach irritation during swallowing. Because multiple manufacturers produce the generic version, the exact shape, coating tint, and the letters or numbers stamped into the tablet (the imprint code) will differ from one manufacturer's product to another, even though the active ingredient and dose are identical. A patient who refills a prescription and receives tablets that look slightly different than last month's bottle has not necessarily received a different drug — pharmacies frequently rotate between approved generic suppliers based on cost and availability. Anyone unsure about a change in appearance should ask the pharmacist to confirm the strength and manufacturer rather than assume an error.
Salt Versus Base: Why "200mg" Is Not the Whole Story
This is the detail that trips up even attentive readers, and it matters clinically. The 200mg figure on the label refers to hydroxychloroquine sulfate, the salt form used to make the drug stable and absorbable as a tablet. The actual hydroxychloroquine base — the part of the molecule that does the pharmacological work — amounts to roughly 155mg per 200mg tablet. This distinction is standard for many drugs dispensed as salts, but it becomes practically important with hydroxychloroquine because dosing guidance for long-term use is given in milligrams per kilogram of real body weight, not simply "one tablet."
The American Academy of Ophthalmology revised its dosing guidance in 2016, recommending that long-term hydroxychloroquine use for lupus or rheumatoid arthritis stay at or below roughly 5mg per kilogram of actual body weight per day, calculated against the base, in order to reduce the risk of a rare but serious complication: hydroxychloroquine retinopathy, a form of retinal damage that can become irreversible if not caught early. Because tablets only come in one fixed strength, prescribers frequently cannot land exactly on a patient's ideal daily dose with whole tablets. This is why regimens such as "one tablet daily" for a smaller patient, or alternating doses like 200mg one day and 400mg the next for a heavier one, are common. The fixed tablet size, in other words, directly shapes how doctors have to structure a dosing schedule, and getting that schedule wrong over years — not months — is the main driver of retinopathy risk. Patients on hydroxychloroquine for more than five years are generally advised to have an annual dilated eye exam, often including optical coherence tomography, specifically to monitor for this.
Generic Equivalence, Manufacturing Differences, and Price
Multiple manufacturers make generic hydroxychloroquine sulfate, and the FDA requires that any generic demonstrate bioequivalence to the reference product — meaning the rate and extent of drug absorbed into the bloodstream must fall within a defined statistical range (generally 80–125%) of the original. This is a real, enforced standard, not a formality, and it is why generic substitution is considered clinically appropriate by regulators and most physicians. Where generics can legitimately differ is in the inactive ingredients: fillers, binders, dyes, and coating agents. These rarely matter, but they occasionally do for patients with specific allergies or sensitivities, which is one more reason to mention any reaction to a pharmacist promptly rather than assume all "hydroxychloroquine 200mg" tablets are chemically interchangeable in every respect.
On price, hydroxychloroquine has been off patent for decades and is inexpensive relative to most modern medications, though the specific cost a patient pays varies enormously by country, insurance formulary, pharmacy, and whether a brand or generic version is dispensed. Costs also fluctuated during periods of high public demand, such as in early 2020, when supply pressure temporarily affected pricing and availability for the lupus and rheumatoid arthritis patients who depend on it long-term. Because pricing changes with market conditions and location, this article will not quote a specific figure; patients wanting a current price should check with their own pharmacy or insurance benefit, which is also the right way to catch any billing error early.
Compounded Liquids and Non-Standard Preparations
Some patients, particularly children or adults who cannot swallow tablets, receive hydroxychloroquine as a liquid suspension prepared by a compounding pharmacy, which crushes commercial tablets and suspends them in a flavored liquid vehicle. This is a legitimate and sometimes necessary practice, but it is worth understanding that a compounded suspension is not FDA-approved in the way the tablet is. Compounded products are not required to undergo the same bioequivalence testing, their stability over time can vary by pharmacy and formula, and dosing accuracy depends heavily on careful preparation and shaking before each dose. For most adults who can swallow a tablet, the standard tablet remains the more predictable and better-studied option. Anyone considering a compounded formulation for a family member should discuss it directly with the prescribing physician and the compounding pharmacist, and should treat it as a different product requiring its own attention rather than a simple substitute.
What Formulation Does — and Does Not — Change About Outcomes
For its approved uses, the evidence behind hydroxychloroquine is substantial. Randomized controlled trials and decades of rheumatology and lupus practice support its role in reducing disease flares and organ damage in systemic lupus erythematosus, and it remains a foundational disease-modifying drug in rheumatoid arthritis, generally in combination with other agents. In this context, formulation matters mainly through the dosing precision issue described above — getting the milligram-per-kilogram target right over years of use — rather than through any difference in fundamental drug activity between one manufacturer's tablet and another.
The picture is very different for COVID-19, where hydroxychloroquine attracted enormous public attention in 2020. Early laboratory (in vitro, cell-culture) studies and small observational reports suggested a possible antiviral effect, and this generated widespread interest. However, larger, better-controlled evidence did not confirm a clinical benefit. The RECOVERY trial, a large randomized platform trial run by the University of Oxford, and the World Health Organization's Solidarity trial, both found no reduction in mortality or hospital stay among COVID-19 patients treated with hydroxychloroquine compared with usual care. The FDA revoked its emergency use authorization for hydroxychloroquine in COVID-19 in June 2020 on this basis, and it has never been approved for that use. No difference in tablet formulation, dose timing, or manufacturer changes that underlying result — the trials tested the same drug used for lupus and arthritis, and the conclusion was about the drug's effect on the virus and the illness, not about how it was packaged. Readers who encounter claims that a particular brand, source, or delivery method of hydroxychloroquine works differently against viral illness should treat such claims with real caution; that is not what the controlled trial evidence shows, and a patient's best protection is an honest conversation with their own physician about what the drug is actually approved and shown to do.
Key takeaway: Hydroxychloroquine is sold in only one form — a 200mg sulfate tablet — and understanding the salt-versus-base dosing math, generic manufacturing standards, and the real trial evidence for its approved uses matters far more to a good outcome than the brand printed on the bottle.